RCS - Arecor Therapeutics - Arecor to present at Oppenheimer conference

Arecor Therapeutics

09/03/2026 07:00

RNS Number : 7348V

Arecor Therapeutics PLC

09 March 2026

 

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference

Cambridge, UK, 9 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be presenting at the Oppenheimer 36th Annual Healthcare MedTech and Services Conference on 16 March. The Arecor team will also be attending the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 11-14 March. Full details for both events are below:

 

Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 16-19 March 2026, online

Sarah Howell will be presenting on Arecor's lead programme AT278, the only ultra-concentrated, ultra-rapid acting insulin, designed to lower patient burden and improve outcomes for people with diabetes in combination with Automated Insulin Delivery (AID) Systems, at the Oppenheimer conference on March 16, 2026 at 9.20am EDT. Click here to register to watch the presentation.  The presentation will also be made available on Arecor's website here after the event. David Ellam, CFO, will also be attending.

 

Advanced Technologies & Treatments for Diabetes (ATTD) - 11-14 March 2026, Barcelona

Sarah Howell (CEO), Jan Jezek (CSO) and David Gerring (CDO) will also be attending ATTD 2026. The conference brings clinicians, diabetes care providers, researchers, industry, investors, reimbursement authorities, and regulators together in order to collaborate to drive rapid progress in diabetes care.

 

For attendees at either conference interested in meeting the Arecor team, please email BD@arecor.com.

-ENDS-

For more information, please contact:

 

Arecor Therapeutics plc
 Dr Sarah Howell, Chief Executive Officer
 David Ellam, Chief Financial Officer
+44 (0) 1223 426060
info@arecor.com
Singer Capital Markets Advisory LLP
 (NOMAD and Broker)
+44 (0) 20 7496 3000
Phil Davies, James Fischer
Vigo Consulting (Financial Communications)Melanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230
arecor@vigoconsulting.com
Vida Strategic Partners (US Investor Relations)
Stephanie Diaz
+1 (415) 675-7401
sdiaz@vidasp.com

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAAKABNPBKDCNK